PharmaShots | Incisive News in 3 Shots

Subscribe Now

skyrizi

AbbVie's Skyrizi (risankizumab-rzaa) Receives FDA's Approval for Moderate to Severe Plaque Psoriasis

AbbVie's Skyrizi (risankizumab-rzaa) Receives FDA's Approval for Moderate to Severe Plaque Psoriasis

April 24, 2019

AbbVie's Skyrizi (risankizumab) Receives Health Canada's Approval for Moderate to Severe Plaque Psoriasis

AbbVie's Skyrizi (risankizumab) Receives Health Canada's Approval for Moderate to Severe Plaque Psoriasis

April 19, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us